Economy · Full coverage
Playtika Reports $731 Million Q2 Revenue with Disney Solitaire Surging
How 3 Israeli newsrooms covered this story — translated into English and compared side by side.
100% center
Center 2Unrated 1
First reported by Globes · 2 hours ago
What happened
Playtika reported $731.1 million in revenue for Q2 2026, with Disney Solitaire revenues surging 288.6% year-over-year. Despite a slight quarterly revenue decline, the company saw strong growth in direct-to-consumer sales and improved profitability, highlighting the success of its long-term gaming strategy.
- 01Playtika’s Q2 2026 revenue totaled $731.1 million, up 5% year-over-year but down 1.8% quarter-over-quarter.
- 02Direct-to-consumer sales grew 63.1% year-over-year to $286.9 million despite a slight quarterly decline.
- 03Disney Solitaire revenue jumped 288.6% year-over-year to $142.4 million, showing strong growth.
- 04Bingo Blitz revenue declined 9.5% year-over-year to $145.1 million, while June’s Journey rose 8.1% to $74.7 million.
- 05Average daily paying users fell 5.2% quarter-over-quarter to 367,000, but conversion rates improved to 4.6%.
- 06CEO Robert Antokol emphasized the company’s focus on long-term player engagement and disciplined execution.
Summary translated & synthesized from the sources below by baba. Read each original for the full report.
Full coverage · 3 outlets
The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.
Related stories
Playtika Negotiates Sale of Israeli SuperPlay to Chinese Gaming Giant TencentJul 20, 2026Golf Group Reports Sharp Profit Growth in Q2 2026 Fueled by Weaker Dollar and Cost Cuts6 hours agoPapaya Gaming Seeks Temporary Stay After $719 Million US Court Ruling3 days agoPalantir Reports 93% Revenue Surge, Raises Full-Year Forecast on Strong US Government and Commercial Growth2 days agoSolarEdge Shares Plunge Over 20% Despite Q2 Revenue Growth on Weak Q3 Forecast1 day agoTeva Reports Strong Q2 Revenue, Raises Full-Year Forecast for Branded DrugsJul 29, 2026